Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Other Non-Current Assets (2016 - 2025)

Haemonetics has reported Other Non-Current Assets over the past 16 years, most recently at $216.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 34.71% year-over-year to $216.1 million; the TTM value through Dec 2025 reached $216.1 million, up 34.71%, while the annual FY2025 figure was $164.1 million, 20.32% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $216.1 million at Haemonetics, up from $208.0 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $216.1 million in Q4 2025 and troughed at $63.2 million in Q2 2022.
  • A 5-year average of $121.8 million and a median of $117.2 million in 2023 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: dropped 10.83% in 2022 and later surged 69.25% in 2023.
  • Year by year, Other Non-Current Assets stood at $66.6 million in 2021, then surged by 55.08% to $103.3 million in 2022, then rose by 23.39% to $127.4 million in 2023, then grew by 25.87% to $160.4 million in 2024, then skyrocketed by 34.71% to $216.1 million in 2025.
  • Business Quant data shows Other Non-Current Assets for HAE at $216.1 million in Q4 2025, $208.0 million in Q3 2025, and $196.3 million in Q2 2025.